Pharma lifts the Trump blues for Ireland

The decision of Merck Sharp Dohme, or MSD as it’s better known in these parts, is more than good news for Dublin but also for Ireland, writes Paul Mills.

It’s a time when it’s very easy to be negative. Whatever happens with Brexit it is sure to hit Irish business.

The US has made it much more attractive for its overseas corporations to repatriate funds and it has cut its corporation taxes, possibly suggesting fewer projects for Ireland.